RBC rates Onyx at outperform

Onyx Pharmaceuticals, Inc. was rated by RBC Capital Markets analyst David Bouchey at outperform, speculative risk after the company's shares suffered a significant one-day decline. The decline is the result of the perception that arose at American Society for Clinical Oncology annual meeting that Nexavar will be relegated to second-line only. Shares of the Emeryville, Calif.-based biopharmaceutical company were up $0.43, or 2.56%, at $17.25 on volume of 4,995,470 shares versus the three-month running average of 1,039,600 shares. (Nasdaq: ONXX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.